SYRACUSE, NY, UNITED STATES, October 5, 2026 /EINPresswire.com/ — Lento Bio, a biotechnology company developing eye drops that reverse age-related changes in the lens, today announced that the company will present its lead program, LB-01, at Eyecelerator @ American Academy of Ophthalmology (AAO) 2026, being held in New Orleans, LA on October 8, 2026.

“Nearly everyone develops presbyopia by their 40s, and it represents the the first symptomatic aging disorder for many people. LB-01 is designed to restore the lens’s natural flexibility and would be the first rejuvenating therapy that acts as disease modifying rather than symptomatic,” said Kris Barnes, PhD, Chief Executive Officer of Lento Bio. “We look forward to sharing our results from our lead program with the ophthalmology community at Eyecelerator.”

Presentation details:
• Presenter: Kris Barnes, PhD
• Date/Time: October 8, 2026, at 1:55 pm CT
• Session: Anterior Segment
• Location: Room 243-245, Ernest N. Morial Convention Center, New Orleans, LA

About LB-01-
LB-01 is an investigational therapeutic in development for presbyopia. It is designed to soften the aging lens by breaking the crosslinks that make it stiff, restoring accommodation and near-vision.

About Lento Bio
Lento Bio is developing first-in-class eye drops that reverse molecular hallmarks of lens aging. For more information, visit lentobio.com.

Kris Barnes
Lento Bio
email us here
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Media gallery

About The Author
Written By: EIN Presswire